AS PER Invoice AS Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: AS PER Invoice AS Pharmaceutical Import Records from India — 3 Products, $115.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AS PER Invoice AS — Pharmaceutical Importer Profile (2026) | 3 Products, $115.7K Trade | TransData Nexus

AS PER Invoice AS

Pharmaceutical Importer · Brazil · Advanced Oncology Focus · $115.7K Total Trade · DGFT Verified

AS PER Invoice AS is a pharmaceutical importer based in Brazil with a total trade value of $115.7K across 3 products in 1 therapeutic categories. Based on 15 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. AS PER Invoice AS sources from 2 verified Indian suppliers, with Vama Lifecare Private Limited accounting for 76.1% of imports.

AS PER Invoice AS — Import Portfolio & Supplier Network

AS PER Invoice AS import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to AS PER Invoice AS?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Vama Lifecare Private Limited	$479.1K	192	76.1%
Vama Health World Llp	$150.7K	40	23.9%

AS PER Invoice AS sources from 2 verified Indian suppliers across .

What Formulations Does AS PER Invoice AS Import?

Formulation	Value	Ships
Harmless medicine for human consumptiondaratumumab concentrate for solution forinfusion 400MG/20ML batch no.	$40.2K	1
Harmless medicine for human consumptiondorzolamide & timolol eye drops i.p. 5mlbatch no. 23159 manufacturing date.	$33.0K	1
Harmless medicine for human consumptionsomatropin 36iu batch no. gt3012 manufacturing date. 08/2022 exp date.	$26.7K	1
Harmless medicine for human consumptionetanercept 50MG batch no. gr5514 manufacturing date. 04/2023 exp date.	$25.9K	2
Harmless medicine for human consumptiontabs. valsartan 160MG batch no. b8968a manufacturing date. 05/2023 exp date.	$24.9K	1
Harmless medicine for human consumptiontube. conjugated estrogen vaginal cream14 g batch no. d95n manufacturing date.	$22.0K	2
Harmless medicine for human consumptiondaratumumab concentrate for solution forinfusion 400MG/20ML batch no.	$20.9K	1
Harmless medicine for human consumptiontabs. olaparib 150 MG batch no. sh763 manufacturing date. aug-22 exp date.	$19.6K	2
Harmless medicine for human consumptionpfs. denosumab 60MG batch no. 1163762 manufacturing date. 02/2023 exp date.	$17.6K	2
Harmless medicine for human consumptiontabs. valsartan 160MG batch no. b8981l manufacturing date. 06/2023 exp date.	$16.2K	1
Harmless medicine for human consumptioninj. abciximab 10MG batch no. amv1a23003 manufacturing date. 08/2023 exp date.	$15.2K	2
Harmless medicine for human consumptiontabs.osimertinib 80MG batch no. flgz manufacturing dt. 01/2023 exp dt.	$15.0K	1
Harmless medicine for human consumptiondaratumumab concentrate for solution forinfusion 400MG/20ML batch no.	$13.1K	1
Harmless medicine for human consumptionetanercept 50MG enbrel 50MG batch no. gr5514 manufacturing date. 04/2023 exp date.	$13.0K	1
Harmless medicine for human consumptioninj. rituximab 500MG/50ML batch no. rb2336a manufacturing date. 07/2023 exp date.	$12.4K	1

AS PER Invoice AS imports 179 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Daratumumab	Advanced Oncology	$74.3K	3	5.6%	2
2	Olaparib	Advanced Oncology	$33.9K	9	3.7%	3
3	Nilotinib	Advanced Oncology	$7.6K	3	0.6%	3

AS PER Invoice AS imports 3 pharmaceutical products across 1 categories into Brazil totaling $115.7K.

AS PER Invoice AS — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

AS PER Invoice AS is a pharmaceutical importer based in Brazil, specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has engaged in 15 shipments from India, totaling an import value of $116,000 USD. The imported products span three distinct formulations within a single therapeutic category, Advanced Oncology, indicating a focused approach to its product portfolio. The top three imported products are Daratumumab ($74,000 USD), Olaparib ($34,000 USD), and Nilotinib ($8,000 USD), collectively accounting for 100% of the company's imports. This concentration suggests a strategic emphasis on oncology treatments, particularly in the realm of advanced cancer therapies.

2Distribution Network

While specific details regarding AS PER Invoice AS's warehouse locations and logistics capabilities are not publicly available, the company's import activities indicate a reliance on efficient distribution networks to manage the importation and distribution of pharmaceutical products. Given the specialized nature of the imported products, it is likely that the company collaborates with logistics providers experienced in handling pharmaceutical goods, ensuring compliance with Brazil's stringent regulatory requirements. The geographic coverage within Brazil is not explicitly detailed, but the focus on advanced oncology products suggests a targeted distribution strategy, potentially serving major urban centers and healthcare facilities equipped to handle such specialized treatments.

3Industry Role

AS PER Invoice AS operates as a pharmaceutical importer, sourcing finished pharmaceutical formulations from India for distribution within Brazil. The company's role in the Brazilian pharmaceutical supply chain is that of a specialized importer, focusing exclusively on advanced oncology treatments. This specialization positions AS PER Invoice AS as a key player in providing critical cancer therapies, particularly in the advanced stages of the disease, to the Brazilian market. By concentrating on this niche, the company addresses a specific segment of the healthcare sector, catering to the needs of oncology specialists and patients requiring advanced treatment options.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — AS PER Invoice AS

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

AS PER Invoice AS demonstrates a high degree of supplier concentration, with 100% of its imports sourced from two Indian suppliers: VAMA LIFECARE PRIVATE LIMITED ($479,000 USD, 76.1% of shipments) and VAMA HEALTH WORLD LLP ($151,000 USD, 23.9% of shipments). This sourcing strategy indicates a strategic choice to establish strong, reliable partnerships with these suppliers, ensuring consistent product quality and supply chain stability. The significant volume of imports from these two suppliers suggests a deep integration and mutual trust, which can lead to favorable terms and prioritized service. However, this concentration also presents a potential risk; any disruptions affecting these suppliers—such as production issues, regulatory challenges, or geopolitical events—could impact AS PER Invoice AS's ability to meet market demand. To mitigate this risk, the company may consider diversifying its supplier base or developing contingency plans to ensure a continuous supply of critical oncology medications.

2Supply Chain Resilience

The resilience of AS PER Invoice AS's supply chain is closely tied to the stability and reliability of its primary suppliers in India. The company's focus on a limited number of suppliers suggests a deep integration, which can lead to streamlined operations and favorable terms. However, this reliance also means that any disruptions affecting these suppliers—such as production delays, regulatory changes, or logistical challenges—could significantly impact AS PER Invoice AS's ability to fulfill its commitments to the Brazilian market. To enhance supply chain resilience, the company might consider establishing relationships with additional suppliers, implementing robust contingency plans, and closely monitoring the regulatory environments in both India and Brazil to anticipate and mitigate potential disruptions.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the regulation of pharmaceutical products is overseen by the Agência Nacional de Vigilância Sanitária (ANVISA), the National Health Surveillance Agency. ANVISA is responsible for ensuring the safety, efficacy, and quality of health-related products and services, including the authorization of clinical trials, active pharmaceutical ingredients (APIs), and the marketing authorization of drugs and biological products. The agency categorizes drugs into various groups, such as new synthetic and semi-synthetic drugs, generic drugs, similar drugs (branded generics), and others, each subject to specific regulatory pathways. For foreign companies, including Indian exporters, to market their products in Brazil, they must establish a partnership with a legally constituted company in Brazil that will assume legal responsibility for marketing authorization, importing, distribution, and post-marketing surveillance within the country. (gov.br)

2Import Licensing & GMP

Importing pharmaceutical products into Brazil requires compliance with ANVISA's regulations, including obtaining the necessary import licenses and ensuring that products meet Good Manufacturing Practices (GMP). ANVISA's Resolution RDC 658/2022 outlines the general GMP guidelines for medicines, aligning with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standards to ensure product quality and consistency. Foreign companies intending to export pharmaceuticals to Brazil must partner with a Brazilian company that holds the appropriate licenses and authorizations, as ANVISA requires that all imported pharmaceutical products be registered and approved before commercialization. (gov.br)

AS PER Invoice AS — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

AS PER Invoice AS's product strategy focuses exclusively on advanced oncology treatments, importing finished pharmaceutical formulations such as Daratumumab, Olaparib, and Nilotinib. This strategic focus aligns with the growing demand for specialized cancer therapies in Brazil, particularly for advanced stages of the disease. The company's emphasis on these specific therapeutic areas suggests a commitment to addressing critical unmet medical needs within the oncology sector, positioning itself as a key supplier of essential cancer treatments in the Brazilian market.

2Sourcing Profile

AS PER Invoice AS's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular focus on oncology treatments. The company has established partnerships with two primary Indian suppliers, VAMA LIFECARE PRIVATE LIMITED and VAMA HEALTH WORLD LLP, indicating a preference for suppliers that can provide high-quality, specialized products. This sourcing approach allows AS PER Invoice AS to leverage India's robust pharmaceutical manufacturing capabilities, particularly in the production of generic oncology drugs, to meet the specific needs of the Brazilian market.

3Market Positioning

Seller's Guide — How to Become a Supplier to AS PER Invoice AS

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with AS PER Invoice AS, particularly those specializing in high-quality oncology products. The company's focused product strategy and established relationships with Indian suppliers indicate a preference for reliable partners capable of meeting stringent quality standards. Indian exporters seeking to become alternative suppliers should ensure they can provide products that align with AS PER Invoice AS's therapeutic focus and comply with both Indian and Brazilian regulatory requirements. Additionally, demonstrating a commitment to quality, reliability, and competitive pricing will be crucial in establishing a successful partnership.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — AS PER Invoice AS

What products does AS PER Invoice AS import from India?

AS PER Invoice AS imports 3 pharmaceutical products across 1 categories. Top imports: Daratumumab ($74.3K), Olaparib ($33.9K), Nilotinib ($7.6K).

Who supplies pharmaceuticals to AS PER Invoice AS from India?

AS PER Invoice AS sources from 2 verified Indian suppliers. The primary supplier is Vama Lifecare Private Limited (76.1% of imports, $479.1K).

What is AS PER Invoice AS's total pharmaceutical import value?

AS PER Invoice AS's total pharmaceutical import value from India is $115.7K, based on 15 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does AS PER Invoice AS focus on?

AS PER Invoice AS imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full AS PER Invoice AS Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.